One Strategy for Updating an Aging Facility

Updating an Aging Facility

Manufacturing line upgrades can create uncertainty for contract manufacturing organizations (CMOs) and their pharmaceutical clients, particularly when clients assume that any facility or equipment change requires a prior approval supplement (PAS). This discussion outlines a regulatory strategy for evaluating changes based on their potential impact on approved processes, product quality, and regulatory filings, while maintaining compliance and minimizing manufacturing downtime.

A key starting point is a strong quality agreement that clearly defines responsibilities between the CMO and its clients. The agreement should establish who is responsible for maintaining and upgrading manufacturing facilities, while recognizing the CMO’s obligation to maintain its facility in compliance with cGMP requirements. FDA guidance on post-approval manufacturing changes also provides opportunities for certain facility and equipment modifications to be documented through an annual report rather than requiring prior approval. Examples include like-for-like replacement of equipment used in aseptic manufacturing when there is no change to the approved process or in-process control limits.

For changes that may generate additional client concerns, a comparability protocol can provide a structured approach to demonstrating that an upgrade will not adversely affect product quality. The protocol may also support an alternative filing strategy and allow engineering and production data to demonstrate equivalency following implementation. By combining clearly defined quality agreement responsibilities, an understanding of post-approval change requirements, and appropriate use of comparability protocols, CMOs can present clients with a documented strategy for implementing necessary facility improvements while managing regulatory risk and reducing potential downtime.

Read the full article: One Strategy for Updating an Aging Facility